SITC 2021 | Phase II trial of AV-GBM-1 in patients with newly diagnosed glioblastoma

Daniela Bota, MD, PhD, The University of California, Irvine, Irvine, CA, talks on the Phase II trial of the dendritic cell vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma. Early results show an improvement in progression-free survival for these patients, with over 20% achieving long-term survival. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.